MRK – Merck & Co., Inc.
Float Short %
1.07
Margin Of Safety %
41
Put/Call OI Ratio
0.69
EPS Next Q Diff
EPS Last/This Y
1.3
EPS This/Next Y
0.27
Price
82.49
Target Price
101.32
Analyst Recom
2.03
Performance Q
2.1
Relative Volume
1.18
Beta
0.35
Ticker: MRK
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-10-06 | MRK | 88.8 | 0.74 | 0.22 | 740053 |
| 2025-10-07 | MRK | 87.61 | 0.72 | 0.53 | 757195 |
| 2025-10-08 | MRK | 86.42 | 0.72 | 0.44 | 763468 |
| 2025-10-09 | MRK | 87.43 | 0.72 | 0.15 | 766193 |
| 2025-10-10 | MRK | 86.17 | 0.70 | 0.41 | 783832 |
| 2025-10-13 | MRK | 85.61 | 0.72 | 0.97 | 738140 |
| 2025-10-14 | MRK | 84.7 | 0.72 | 0.51 | 747415 |
| 2025-10-15 | MRK | 84.15 | 0.73 | 0.25 | 753216 |
| 2025-10-16 | MRK | 84.04 | 0.72 | 0.49 | 761958 |
| 2025-10-17 | MRK | 84.77 | 0.72 | 0.13 | 768571 |
| 2025-10-20 | MRK | 86.32 | 0.62 | 0.17 | 694056 |
| 2025-10-21 | MRK | 87.63 | 0.63 | 1.12 | 697933 |
| 2025-10-22 | MRK | 87.64 | 0.65 | 0.32 | 708753 |
| 2025-10-23 | MRK | 87.2 | 0.67 | 0.65 | 704814 |
| 2025-10-24 | MRK | 87.48 | 0.67 | 0.58 | 706402 |
| 2025-10-27 | MRK | 88 | 0.73 | 0.52 | 652900 |
| 2025-10-28 | MRK | 87.05 | 0.73 | 1.04 | 655501 |
| 2025-10-29 | MRK | 86.5 | 0.73 | 0.86 | 661288 |
| 2025-10-30 | MRK | 86.21 | 0.74 | 0.43 | 681559 |
| 2025-10-31 | MRK | 86.06 | 0.74 | 0.36 | 693489 |
| 2025-11-03 | MRK | 82.57 | 0.69 | 0.56 | 652943 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-10-06 | MRK | 88.79 | 50.4 | 8191.8 | 8.93 |
| 2025-10-07 | MRK | 87.58 | 50.4 | 8046.9 | 8.93 |
| 2025-10-08 | MRK | 86.43 | 50.3 | 8052.9 | 8.93 |
| 2025-10-09 | MRK | 87.47 | 50.3 | 8716.7 | 8.93 |
| 2025-10-10 | MRK | 86.03 | 50.2 | 7965.9 | 8.93 |
| 2025-10-13 | MRK | 85.64 | 50.2 | 8294.6 | 8.93 |
| 2025-10-14 | MRK | 84.68 | 50.3 | 8093.9 | 8.91 |
| 2025-10-15 | MRK | 84.13 | 50.3 | 8081.7 | 8.91 |
| 2025-10-16 | MRK | 83.88 | 49.9 | 8183.2 | 8.91 |
| 2025-10-17 | MRK | 84.78 | 49.9 | 8512.2 | 8.91 |
| 2025-10-20 | MRK | 86.29 | 49.9 | 8703.5 | 8.88 |
| 2025-10-21 | MRK | 87.60 | 49.9 | 8631.2 | 8.88 |
| 2025-10-22 | MRK | 87.61 | 49.7 | 8250.1 | 8.88 |
| 2025-10-23 | MRK | 87.20 | 49.7 | 8133.1 | 8.88 |
| 2025-10-24 | MRK | 87.47 | 49.5 | 8338.0 | 8.89 |
| 2025-10-27 | MRK | 88.00 | 49.5 | 8402.0 | 8.89 |
| 2025-10-28 | MRK | 87.03 | 49.6 | 7971.0 | 8.89 |
| 2025-10-29 | MRK | 86.54 | 49.6 | 8109.0 | 8.89 |
| 2025-10-30 | MRK | 86.28 | 49.6 | 8164.5 | 8.89 |
| 2025-10-31 | MRK | 85.98 | 24.8 | 8164.1 | 8.95 |
| 2025-11-03 | MRK | 82.49 | 24.8 | 7217.3 | 8.95 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-10-06 | MRK | -0.17 | -0.60 | 1.11 |
| 2025-10-07 | MRK | -0.17 | -0.60 | 1.11 |
| 2025-10-08 | MRK | -0.17 | -0.60 | 1.11 |
| 2025-10-09 | MRK | -0.17 | -0.60 | 1.11 |
| 2025-10-10 | MRK | -0.17 | -0.60 | 1.01 |
| 2025-10-13 | MRK | -0.17 | -0.48 | 1.01 |
| 2025-10-14 | MRK | -0.17 | -0.48 | 1.01 |
| 2025-10-16 | MRK | -0.17 | -0.48 | 1.01 |
| 2025-10-17 | MRK | -0.17 | -0.48 | 1.01 |
| 2025-10-20 | MRK | -0.17 | -0.62 | 1.01 |
| 2025-10-21 | MRK | -0.17 | -0.62 | 1.01 |
| 2025-10-22 | MRK | -0.17 | -0.62 | 1.01 |
| 2025-10-23 | MRK | -0.17 | -0.62 | 1.01 |
| 2025-10-24 | MRK | -0.17 | -0.62 | 1.01 |
| 2025-10-27 | MRK | -0.17 | -0.72 | 1.07 |
| 2025-10-28 | MRK | -0.17 | -0.72 | 1.07 |
| 2025-10-29 | MRK | -0.17 | -0.72 | 1.07 |
| 2025-10-30 | MRK | 0.00 | -0.72 | 1.07 |
| 2025-10-31 | MRK | 0.00 | -0.72 | 1.07 |
| 2025-11-03 | MRK | 0.00 | -0.69 | 1.07 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
2.15
Avg. EPS Est. Next Quarter
2.25
Insider Transactions
Institutional Transactions
-0.69
Beta
0.35
Average Sales Estimate Current Quarter
16307
Average Sales Estimate Next Quarter
16154
Fair Value
116.56
Quality Score
97
Growth Score
84
Sentiment Score
16
Actual DrawDown %
38.7
Max Drawdown 5-Year %
-43.4
Target Price
101.32
P/E
10.91
Forward P/E
8.79
PEG
1.06
P/S
3.22
P/B
4.21
P/Free Cash Flow
14
EPS
7.56
Average EPS Est. Cur. Y
8.95
EPS Next Y. (Est.)
9.22
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
29.75
Relative Volume
1.18
Return on Equity vs Sector %
7.8
Return on Equity vs Industry %
-2.9
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.02
EBIT Estimation
7217.3
Merck & Company, Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 73000
Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
stock quote shares MRK – Merck & Co., Inc. Stock Price stock today
news today MRK – Merck & Co., Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch MRK – Merck & Co., Inc. yahoo finance google finance
stock history MRK – Merck & Co., Inc. invest stock market
stock prices MRK premarket after hours
ticker MRK fair value insiders trading